Kampanjeplan Ocugen, Inc.
Avansert tidsplan
Enkel graf
Om selskapet
Ocugen, Inc., биофармацевтическая компания, работающая на клинической стадии, занимается открытием, разработкой и коммерциализацией трансформирующих методов лечения болезней слепоты. В линейку продуктов компании входят OCU200, новый гибридный белок, который находится на стадии доклинической разработки для лечения влажной AMD, диабетической ретинопатии и диабетического макулярного отека; OCU400 для лечения пигментного ретинита, группы редких генетических заболеваний; и OCU410, который находится на стадии доклинической разработки для лечения сухой AMD. Ocugen, Inc. flere detaljer| IPO date | 2014-12-03 |
|---|---|
| ISIN | US67577C1053 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | https://www.ocugen.com |
| Prisendring per dag: | 0% (0.7866) |
|---|---|
| Prisendring per uke: | -12.56% (0.8996) |
| Prisendring per måned: | -7.72% (0.8524) |
| Prisendring over 3 måneder: | -17.19% (0.9499) |
| Prisendring over seks måneder: | -57.02% (1.83) |
| Prisendring per år: | +31.32% (0.599) |
| Prisendring over 3 år: | -78.09% (3.59) |
| Prisendring over 5 år: | +38.49% (0.568) |
| Prisendring over 10 år: | 0% (0.7866) |
| Prisendring siden begynnelsen av året: | -3.39% (0.8142) |
|
|
Undervurdering
|
Effektivitet
|
|||||||||||||||||||||||||||||||||||||
Utbytte
|
Plikt
|
Vekstimpuls
|
|||||||||||||||||||||||||||||||||||||
| Institusjoner | Volum | Dele, % |
|---|---|---|
| Vanguard Group Inc | 12039918 | 4.69 |
| Blackrock Inc. | 3693281 | 1.44 |
| Geode Capital Management, LLC | 2929948 | 1.14 |
| Luminus Management, LLC | 1626583 | 0.63 |
| State Street Corporation | 835826 | 0.33 |
| Northern Trust Corporation | 509749 | 0.2 |
| Group One Trading, L.P. | 502051 | 0.2 |
| Millennium Management LLC | 410963 | 0.16 |
| Verition Fund Management, LLC | 400000 | 0.16 |
| Susquehanna International Group, LLP | 345591 | 0.13 |
| ETF | Dele, % | Lønnsomhet for året, % | Utbytte, % |
|---|---|---|---|
| Direxion Daily S&P Biotech Bull 3x Shares | 0.07523 | 4067.92 | 0.25924 |
| SPDR S&P Kensho New Economies Composite ETF | 0.07359 | 15.71 | 0.88486 |
| iShares Micro-Cap ETF | 0.07219 | 13.79 | 1.54048 |
| Goldman Sachs ActiveBeta US Small Cap Equity ETF | 0.04072 | 31.36 | 1.41955 |
iShares Russell 2000 Growth ETF
|
0.0211 | 38.04 | 0.6026 |
| Vanguard Russell 2000 Growth ETF | 0.02 | 17.39 | 0.60264 |
| Vanguard Russell 2000 ETF | 0.01 | 14.37 | 1.48801 |
ProShares UltraPro Russell2000
|
0.00614 | 89.82 | 1.47873 |
| ProShares Hedge Replication ETF | 0.00175 | 5.92 | 1.47892 |
| iShares Russell 3000 ETF | 0.00082 | 23.61 | 1.43482 |
| Vanguard Russell 3000 ETF | 0 | 31.87 | 1.43817 |
| Veileder | Stillingstittel | Betaling | Fødselsår |
|---|---|---|---|
| Dr. Uday B. Kompella Ph.D. | Co-founder & Independent Director | 56.72k | 1967 (58 år) |
| Dr. Arun Upadhyay Ph.D. | Chief Scientific Officer and Head of Research & Development | N/A | 1983 (42 år) |
| Ms. Tiffany J. Hamilton M.B.A. | AVP & Head of Corporate Communications | N/A | |
| Mr. Michael Shine M.B.A. | Senior Vice President of Commercial | N/A | |
| Ms. Jyothy Pillai M.S. | VP & Head of Regulatory & Quality | N/A | |
| Dr. Shankar Musunuri M.B.A., Ph.D. | Co-Founder, CEO & Chairman | 1.2M | 1964 (61 år) |
| Mr. Michael Breininger CPA, M.B.A. | Chief Accounting Officer & Corporate Controller | N/A | 1983 (42 år) |
| John Kouch J.D. | General Counsel | N/A | |
| Dr. Huma Qamar CMI, M.D., M.P.H. | Chief Medical Officer | N/A | 1984 (41 år) |
| Ms. Kristen Craft | Head of People & Culture |
Adresse: United States, Malvern, PA , 263 Great Valley Parkway - åpne i Google maps, åpne Yandex-kart
Nettsted: https://www.ocugen.com
Nettsted: https://www.ocugen.com
